1 / 54

Rachel Schiff Breast Center Baylor College of Medicine

Estrogen Receptor and EGFR/HER2 Pathways Cross Talk in Breast Cancer Endocrine Resistance. Rachel Schiff Breast Center Baylor College of Medicine. 2/2003. Endocrine Therapies. Lower E level in tumor. Selective ER modulators; antagonist vs. agonist activity.

wright
Télécharger la présentation

Rachel Schiff Breast Center Baylor College of Medicine

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Estrogen Receptor and EGFR/HER2 Pathways Cross Talk in Breast Cancer Endocrine Resistance Rachel Schiff Breast Center Baylor College of Medicine 2/2003

  2. Endocrine Therapies • Lower E level in tumor. • Selective ER modulators; antagonist vs. agonist activity. • ER modulators with pure antagonist activity. • High dose estrogens, progestins, androgens.

  3. Tamoxifen (SERM) • Agonist activity: bone, endometrium, liver, brain (cognitive function), clotting. • Antagonist activity: breast, vagina, brain (hot flashes). • Breast cancer – treatment benefit: • Adjuvant therapy: 50% reduction in recurrence. • Metastatic disease: disease control. • prevention: 50% reduction.

  4. Major Problem • RESISTANCE • De novo • Acquired

  5. ER Function – 2002/3 Classical E Coregulators Activators Repressors ER ER E E Tumor Growth ER ER mRNA ERE TARGET GENE

  6. ER Fos Jun mRNA ER Function – 2002/3 (con’t) Non Classical ER ERK 1,2 PI3K AP-1 GROWTH

  7. ER Function – 2002/3 (con’t) Growth Factor Crosstalk P P ERSignaling ER - CoA = ERK 1,2 Proliferation AKT Survival JNK, p38 MAPK Stress, Cytokines

  8. Breast Tumor Growth E ER- CoA Growth GF Stress

  9. Activation of the EGFR/HER2 Signaling Pathway Leads to Tamoxifen Resistance • Clinical studies • HER2 overexpression predicts a poor response to tamoxifen therapy • Preclinical studies • Overexpression of HER2 or its stimulation by HRG leads to tamoxifen resistance de novo • Acquired tamoxifen resistance in MCF-7 cells is associated with EGFR overexpression

  10. De novo Tam-R Tam-S Tam-R MCF7 MCF7/HER2 In vivo Model of Endocrine Resistance Ovx Athymic Mice Tumor volume (mm3) 1200 E2 1000 800 600 Tam 400 200 0 0 21 49 77 105 Days (Benz, et al., Breast Cancer Res Treat, 1992)

  11. Agonist activity GF ER-GF Cross-Talk and CoAs in and the Agonist/ Antagonist Activity of Tamoxifen CoR Antagonist activity P E2 ER CoA

  12. Agonist activity ER-GF Cross-Talk and CoAsin the Agonist/ Antagonist Activity of Tamoxifen CoR Antagonist activity P Tam ER CoA

  13. P P HER-2 Genomic Non-genomic ER-GF Cross-Talk and CoAsin the Agonist/ Antagonist Activity of Tamoxifen CoR Antagonist activity P Tam ER CoA Agonist activity

  14. Breast Tumor Endocrine Resistance Tam ER- CoA EGFR/HER2

  15. Tam ER- CoA Breast Tumor Endocrine Resistance + EGFR/HER2

  16. Tam Hormonal Resistance ER- CoA Tumor Growth Breast Tumor Endocrine Resistance + EGFR/HER2

  17. Hypothesis (1) Coactivators Corepressors ER Agonist Antagonist Tamoxifen GF Signaling Tumors with high levels of HER2andcoactivators should be relatively resistant to tamoxifen

  18. AIB1 / SRC-3 • CoA in SRC family. • Binds ER; augments ER signaling. • Overexpressed in 65% breast cancer. • Amplified in 5-10%. • Phosphorylated (activated) by ERK1/2, JNK, p38. •  tam agonist activity.

  19. AIB1 and Tamoxifen Benefit in the Adjuvant Setting • 316 patients, primary breast ca, N+ • -119 no adjuvant systemic therapy • -187 adjuvant tamoxifen • -median follow-up 8 years • Western blot analyses for AIB1 • Correlated with patient and tumor variables HER-2 • Effect on DFS

  20. AIB1 and DFS No Adjuvant Therapy Tamoxifen Adjuvant Therapy 1.00 1.00 0.75 0.75 Low High n=141 n = 29 Proportion DFS 0.50 0.50 High n=46 0.25 0.25 Low n = 90 0.00 0.00 0 20 40 60 80 100 120 0 20 40 60 80 100 120 Time in months Time in months p-value=0.018 p-value=0.22 Osborne et al. ASCO 2002

  21. AIB1 / HER-2 and DFS Tamoxifen Adjuvant Therapy 1.00 0.75 All others Proportion DFS 0.50 n = 162 0.25 AIB1 high / HER2 high n = 25 p-value=0.0024 0.00 0 20 40 60 80 100 120 Time in months

  22. Summary • AIB1 with HER-2, is a strong predictive marker of tam resistance. • Blocking GF pathways and/or AIB1 may reverse tam resistance.

  23. Tam Hormonal Resistance ER- CoA Tumor Growth Breast Tumor Endocrine Resistance + EGFR/HER2

  24. Iressa (ZD1839, Gefitinib) • Selective EGFR tyrosine kinase inhibitor • Blocks EGFR and HER2 signaling Hypothesis (2): Iressa can block tamoxifen- stimulated growth of HER2 overexpressing tumors by eliminating the cross-talk that causes tamoxifen’s agonist activity

  25. De novo Tam-R Tam-S Tam-R MCF7 MCF7/HER2 In vivo model of endocrine resistance Tumor volume (mm3) 1200 1000 800 600 Tam 400 200 0 0 21 49 77 105 Days (Benz, et al., Breast Cancer Res Treat, 1992)

  26. MCF-7/HER2

  27. Experimental design (Endocrine sensitivity of HER2+ tumors) E2 Randomize E2 _E2 TAM MCF-7 HER2

  28. Endocrine sensitivity of HER2 tumors 1400 1200 E2 1000 800 Tumor volume 600 400 200 0 1 30 60 90 120 Days

  29. Endocrine sensitivity of HER2 tumors 1400 1200 E2 1000 800 Tumor volume 600 400 -E2 200 0 1 30 60 90 120 Days

  30. Endocrine sensitivity of HER2+ tumors 1400 1200 TAM E2 1000 800 Tumor volume 600 400 -E2 200 0 1 30 60 90 120 Days

  31. Response to letrozole and tamoxifen in the neoadjuvant setting EGFR/HER2EGFR/HER2 _+ Letrozole 54% 88% Tamoxifen 42% 21% Ellis et al., J Clin Oncol. (2001) 19 3808-16

  32. Experimental design (Iressa effect on endocrine treatment of HER2+ tumors) Iressa + E2 - Randomize E2 + _E2 - + TAM - MCF-7 HER2

  33. Iressa effect on endocrine treatment of HER2 tumors 1400 1200 E2 1000 E2+Iressa 800 Tumor volume 600 400 200 0 1 30 60 90 120 Days

  34. Iressa effect on endocrine treatment of HER2 tumors 1400 1200 TAM E2 1000 E2+Iressa 800 Tumor volume 600 400 TAM+Iressa 200 0 1 30 60 90 120 Days

  35. Iressa effect on endocrine treatment of HER2 tumors 1400 1200 TAM E2 1000 E2+Iressa 800 Tumor volume 600 400 TAM+Iressa 200 0 1 30 60 90 120 Days

  36. Iressa effect on endocrine treatment of HER2 tumors 1400 1200 E2 1000 E2+Iressa 800 Tumor volume 600 - E2 400 -E2+Iressa 200 0 1 30 60 90 120 Days

  37. Hypothesis (3): Targeting the EGFR/HER2 pathway will delay the development of acquired resistance to tamoxifen in tumors with normal levels of EGFR/HER2. Tam-S Tumor volume (mm3) Tam-R 1200 1000 800 Tam 600 400 200 0 0 21 49 77 105 Days

  38. - - - Experimental Design (Iressa and endocrine treatment of MCF-7 tumors) Iressa E2 + Randomize E2 + _E2 TAM + MCF-7

  39. Iressa Effect on E2-StimulatedMCF-7 Xenografts 1400 1200 E2+ Iressa E2 1000 800 Tumor volume 600 400 200 0 0 14 28 42 56 70 84 98 112 126 140 154 168 182 196 210 Days

  40. ZD1839 Effect on Tamoxifen Therapy in MCF-7 Xenografts 1400 1200 E2+ Iressa TAM E2 1000 800 Tumor volume TAM+Iressa 600 400 200 0 0 14 28 42 56 70 84 98 112 126 140 154 168 182 196 210 Days

  41. Iressa Effect on Tamoxifen Therapy in MCF-7 Xenografts 1400 1200 E2+ Iressa TAM E2 1000 800 Tumor volume TAM+Iressa 600 400 200 0 0 14 28 42 56 70 84 98 112 126 140 154 168 182 196 210 Days

  42. Iressa Effect on Estrogen Deprivation 1400 -E2 1200 E2+ Iressa E2 1000 800 Tumor volume - E2+ Iressa 600 400 200 0 0 14 28 42 56 70 98 84 126 154 112 140 Days

  43. Conclusions • Molecular cross-talk increases tamoxifen agonist activity in tumors with high HER-2 (de novo resistance). • Cross-talk also contributes to tamoxifen agonist activity acquired during treatment • (low HER-2). • Receptor TKIs can block this cross-talk, improve tamoxifen performance, and overcome or delay resistance.

  44. Conclusions HER2+ breast tumors • Tamoxifen stimulates growth as a mechanism of de novo resistance • Estrogen deprivation inhibits tumor growth Iressa • Modestly affects as a monotherapy • Inhibits tamoxifen-stimulated growth • Delays resistance to estrogen deprivation

  45. Conclusions Breast tumors with normal low HER2 • Tamoxifen is an effective antiestrogen, but tumors will acquire resistance Iressa • No effect as a monotherapy • Delays acquired resistance to tamoxifen • No significant benefit when combined with estrogen deprivation

  46. Conclusion • ER-targeted therapy combined with EGFR/HER2 inhibitors like Iressa should be tested in clinical trials to delay de novo and acquired resistance. ? Agonist Breast/ Uterus “Optimal SERM” SERM + TKI Agonist Bone/LM

  47. Collaborators • Baylor Breast Center • Shou Jiang • Suleiman Massarweh • Margaret DiPietro • Kent Osborne • Powel Brown • Syed Mohsin/Craig Allred • Sue Hilsenbeck • AstraZeneca • Alan Wakeling

  48. P-ER, HER2, MAPK, AIB1 Iressa Proliferation ER-dependent transcription Effect of Iressa on ER and GF Pathways MCF7 (Tam sensitive) MCF7/HER2 (Tam resistant)

More Related